HAE in the News

The articles listed below are various press releases on Hereditary Angioedema

---

Page#:  1  2  3  4  5  6  7  8  9  10 


Lev Presents Results of Phase III Study Supporting Safety and Efficacy of Cinryze(TM) (C1 inhibitor) as Prophylactic Therapy for
Lev Pharmaceuticals, Inc. (OTCBB:LEVP.OB) today announced the presentation of results from a Phase III study examining the efficacy and safety of prophylactic use of its C1 inhibitor (C1INH) replacement therapy, Cinryze(TM), in patients with hereditary angioedema (HAE). The findings, presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI), demonstrated that prophylactic use of Cinryze significantly decreases the number of attacks in HAE patients. ...more


C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, Accordin
Data presented at AAAAI 64th Annual Meeting also show that C1-INH is effective treatment for HAE attacks across all body sites ...more


CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
KING OF PRUSSIA, Pa., March 6 /PRNewswire/ -- CSL Behring has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval to market its C1-esterase inhibitor concentrate in the United States for the treatment of hereditary angioedema (HAE), a rare and serious genetic disorder. ...more


Lev Pharmaceuticals Receives Complete Response Letter for Cinryze(TM)
Lev Pharmaceuticals, Inc. (OTCBB:LEVP.OB - News) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) related to its biologics license application (BLA) for Cinryze™ (C1 inhibitor) for both the acute and prophylactic treatment of hereditary angioedema (HAE), or C1 inhibitor deficiency. ...more


FDA Accepts Icatibant NDA
German drugmaker Jerini’s new drug application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) has been accepted by the FDA and granted priority review. ...more


CSL says angioedema drug meets goals of trial
CSL Limited (CSL.AX: Quote, Profile, Research) said on Monday its treatment for hereditary angioedema, a rare genetic disorder that can lead to life-threatening swelling of body tissues, met the primary and secondary goals of a late-stage clinical trial. ...more


Novel Therapies May At Last Bring Relief for U.S. Hereditary Angioedema Patients
Although there is currently no treatment approved by the Federal Drug Administration (FDA) for acute attacks of hereditary angioedema (HAE) – a genetic disease causing swelling of extremities, face and internal organs that can be life-threatening – hope is on the horizon according to a team of experts presenting the latest research at the Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Dallas. ...more


Lev Presents Significant Data from Pivotal Phase III Trial of . Cinryze(TM) in Acute Treatment of Hereditary Angioedema at ACAAI
Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP) today announced that investigators presented results from a pivotal, Phase III trial of Cinryze(TM) (C1 inhibitor), in patients with acute attacks of hereditary angioedema (HAE), also known as C1 Inhibitor Deficiency, a genetic condition that causes recurrent and potentially-life threatening inflammation in the larynx, abdomen, face, extremities and urogenital tract. ...more


Lev Pharmaceuticals Amends Cinryze BLA to Include Prophylactic Data
Lev Pharmaceuticals, Inc. (OTCBB:LEVP.OB) today announced the submission of an amendment to its pending Biologics License Application (BLA) for Cinryze (C1 inhibitor) for the treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency. The amendment includes the data from the Company's pivotal U.S. ...more


Pharming completes treatments trials on Rhucin drug in US; results favourable
Pharming NV said it has completed randomized treatments in its North American clinical trial assessing the safety and efficacy of Rhucin to treat acute attacks of hereditary angioedema (HAE), and that all patients responded favourably. ...more


Page #:  1  2  3  4  5  6  7  8  9  10 

The US Hereditary Angioedema Assoc., Seven Waterfront Plaza, 500 Ala Moana Blvd., Suite 400, Honolulu, HI 96813, (866) 798-5598

The US HAEA's 2010 corporate sponsors